President Trump Orders Pharma Firms to Slash Drug Prices to MFN Rates
NewsPresident Trump mandates pharmaceutical companies cut U.S. drug prices to MFN rates within 60 days.
- President Trump orders drug price cuts to MFN levels.
- Pharmaceutical firms face government action if non-compliant.
- Sharp decline in pharma stock prices observed.
President Trump issued a mandate to pharmaceutical companies demanding drug price reductions within 60 days to align with international rates, with a commitment to employ comprehensive federal measures.
This directive impacts pharmaceutical stocks, causing market volatility, though no direct effects on major cryptocurrencies have been observed. Trump’s initiative emphasizes government intervention in drug pricing policies.
President Donald Trump has issued an executive order for drug prices to be reduced to the “most-favored-nation” rates within 60 days. This move revives a previous proposal aimed at reducing drug prices to match other developed countries.
Trump sent official communications to top pharmaceutical companies, including Pfizer and Johnson & Johnson, demanding compliance with the new pricing policy. The order emphasizes the use of “every tool” to ensure adherence. As President Trump has stated, “If you refuse to step up, the federal government will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices.”
The announcement has caused a sharp decline in pharmaceutical stock prices, reflecting investor concerns over potential revenue impacts. Widespread stock market volatility is observed as companies assess compliance strategies.
Financial analysts note possible political implications as healthcare remains a key policy issue under Trump’s leadership. The pharmaceutical industry is bracing for significant regulatory challenges following this mandate.
Public reaction remains muted with no official statements from involved companies. The lack of response underscores companies’ caution in addressing policy shifts. Monitoring for further developments remains crucial for stakeholders.
Historically, similar initiatives have sparked market volatility but left cryptocurrencies unaffected. Analysts anticipate the order could lead to substantial changes in pharmaceutical pricing structures, potentially affecting global market dynamics.
More From Crypto News
Aster (ASTER) Rises 4.88% in 24 Hours: What the Data Shows
Aster (ASTER) is trading at $0.655837, up 4.88% over the past 24 hours, according to CoinGecko data as of 19:13 UTC on November 11, 2026.
Bitcoin Misses Stock Rebound as ETF Outflows Hit Day Four
Bitcoin failed to follow a broad equity rebound on November 11, trading near $73,993 while Nasdaq-100 futures climbed 1.7% after CoreWeave posted an earnings be...
OCC Clears Coinbase National Trust Company for Crypto Custody
The OCC issued its decision in CD-1370 , formally authorizing Coinbase National Trust Company to operate as a federally chartered trust bank focused on digital-...
Reported Ankr Ethereum Bridge Drain Exceeds $303,000, The Defiant Says
The Ankr Ethereum Bridge was drained of more than $303,000 in an exploit carried out across five transactions.
Binance CFO Steps Down After Reported Hack, Co-CEO Cites Planned Transition
Binance’s chief financial officer has stepped down, the exchange confirmed, with the departure landing nine days after the platform suffered what has been descr...
US Treasury Takes Action Against MEXC Over Alleged $16B in Sanctions-Linked Transactions
The Treasury press release identifies MEXC as the subject of the action and ties the exchange to transaction flows connected to three sanctioned or adversarial...
